Short Term Rating on Hologic (HOLX)

Hologic (HOLX) has an average broker rating of 1.88, which is interpreted as a Buy, as rated by 16 equity analysts. Nonetheless, 9 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 7 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

Hologic (HOLX) has been rated by 12 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $46 and the lowest price target forecast is $38. The average forecast of all the analysts is $42.25 and the expected standard deviation is $2.56.

For the current week, the company shares have a recommendation consensus of Buy.


Hologic (NASDAQ:HOLX): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $35.64 and $35.35 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $35.92. The buying momentum continued till the end and the stock did not give up its gains. It closed at $35.71, notching a gain of 0.28% for the day. The total traded volume was 1,690,296 . The stock had closed at $35.61 on the previous day.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.